The expanding therapeutic armamentarium for pulmonary arterial hypertension (PAH), including the recent approval of sotatercept, is shifting treatment goals beyond achieving low-risk status towards haemodynamic improvement and right ventricular (RV) recovery. In this context, there is growing interest in echocard...
E. G. Ortiz, I. M. de Miguel, A. Cruz-Utrilla et al.· European Heart Journal· 0 citations
This study analysed the temporal transition in therapeutic strategies, from the selection of candidates for PEA, the progressive introduction of BPA beginning in 2013, and the development of targeted medical therapies for CTEPH.
M. L. Coronel, B. Arreola, A. C. Utrilla et al.· European Heart Journal· 0 citations
Clinical and hemodynamic outcomes for all therapeutics strategies in OA cohort showed significant benefit from interventional procedures across all evaluated variables, andInterventional therapies – especially BPA- were the most frequently applied and yielded significant clinical and hemodynamic benefits, with excellen...
M. L. Coronel, B. Arreola, A. C. Utrilla et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.